Your browser doesn't support javascript.
loading
Radiomic Biomarkers of Locoregional Recurrence: Prognostic Insights from Oral Cavity Squamous Cell Carcinoma preoperative CT scans.
Ren, Lei; Ling, Xiao; Alexander, Gregory; Molitoris, Jason; Choi, Jinhyuk; Schumaker, Lisa; Mehra, Ranee; Gaykalova, Daria.
Afiliação
  • Ren L; University of Maryland School of Medicine.
  • Ling X; University of Maryland School of Medicine.
  • Alexander G; Thomas Jefferson University.
  • Molitoris J; University of Maryland School of Medicine.
  • Choi J; Kosin University Gospel Hospital.
  • Schumaker L; University of Maryland School of Medicine.
  • Mehra R; University of Maryland School of Medicine.
  • Gaykalova D; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; Marlene & Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center; Institute for Genome Sciences, U.
Res Sq ; 2024 Jan 22.
Article em En | MEDLINE | ID: mdl-38343846
ABSTRACT
This study aimed to identify CT-based imaging biomarkers for locoregional recurrence (LR) in Oral Cavity Squamous Cell Carcinoma (OSCC) patients. Our study involved a retrospective review of 78 patients with OSCC who underwent surgical treatment at a single medical center. An approach involving feature selection and statistical model diagnostics was utilized to identify biomarkers. Two radiomics biomarkers, Large Dependence Emphasis (LDE) of the Gray Level Dependence Matrix (GLDM) and Long Run Emphasis (LRE) of the Gray Level Run Length Matrix (GLRLM) of the 3D Laplacian of Gaussian (LoG σ = 3), have demonstrated the capability to preoperatively distinguish patients with and without LR, exhibiting exceptional testing specificity (1.00) and sensitivity (0.82). The group with LRE > 2.99 showed a 3-year recurrence-free survival rate of 0.81, in contrast to 0.49 for the group with LRE ≤ 2.99. Similarly, the group with LDE > 120 showed a rate of 0.82, compared to 0.49 for the group with LDE ≤ 120. These biomarkers broaden our understanding of using radiomics to predict OSCC progression, enabling personalized treatment plans to enhance patient survival.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article